Microbot Medical Inc. (CY9D)
XSTU 
Summary
CY9D Chart
After Plunging 22.6% in 4 Weeks, Here's Why the Trend Might Reverse for Microbot Medical (MBOT)
Microbot Medical (MBOT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Microbot Medical Inc. (MBOT) Shareholder/Analyst Call Transcript
Microbot Medical Inc. (MBOT) Shareholder/Analyst Call Transcript
Microbot Medical Inc. (MBOT) Reports Q1 Loss, Misses Revenue Estimates
Microbot Medical Inc. (MBOT) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.08 per share a year ago.
Microbot Medical Inc. (CY9D) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Microbot Medical Inc. ever had a stock split?
Microbot Medical Inc. Profile
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Harel Gadot CEO | XSTU Exchange | 59503A204 CUSIP |
| US Country | 43 Employees | - Last Dividend | 29 Nov 2016 Last Split | 25 Mar 1992 IPO Date |
Overview
Microbot Medical Inc. stands as a notable entity in the realm of pre-clinical medical device innovation, with its operations rooted in the United Kingdom. The company is primarily focused on the research, design, and development of cutting-edge robotic endoluminal surgery devices, aiming to revolutionize the minimally invasive surgery sector. Founded in 2010 and headquartered in Braintree, Massachusetts, Microbot Medical Inc. is dedicated to advancing the field of minimally invasive surgeries through its innovative technologies. Furthermore, the company has established a strategic collaboration agreement with Stryker Corporation, emphasizing its commitment to technology co-development and positioning itself at the forefront of medical device innovation.
Products and Services
Microbot Medical Inc. offers a portfolio of products focused on enhancing the efficiency and safety of minimally invasive surgical procedures through advanced robotics and innovative device solutions:
- LIBERTY Endovascular Robotic System: This flagship product marks a significant advancement in the realm of endovascular surgeries. The LIBERTY system allows physicians to conduct catheter-based procedures from outside the catheterization laboratory, significantly reducing the risks associated with radiation exposure, physical strain, and the potential for cross-contamination. Designed for use in cardiovascular, peripheral, and neurovascular spaces, LIBERTY represents a leap forward in robotic-assisted vascular interventions.
- NovaCross: As part of Microbot Medical Inc.'s innovative product lineup, NovaCross is a pioneering intellectual property and technological solution in the field of intraluminal revascularization. It features a unique anchoring mechanism and an integrated microcatheter, designed to enhance the precision and safety of intraluminal procedures. This product underscores the company's commitment to developing novel solutions for complex medical challenges encountered in the surgical landscape.
